NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
LOS ANGELES, Jan. 22, 2025 (GLOBE NEWSWIRE) — NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating ADHD, today announced the filing of a new patent related to use of eTNS for treating neurodevelopmental disorders. The patent filing, Trigeminal Nerve Stimulation as Treatment for Neurodevelopmental Disorders […]